Regeneron’s (REGN) odronextamab was granted FDA orphan designation as a treatment of splenic marginal zone lymphoma, according to a post to the ...

With a market cap of $62.4 billion, Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and ...

Regeneron's oncology platform is poised to be a significant growth driver in the next decade. Read why REGN stock remains a ...

Looking back on immuno-oncology stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Regeneron ...

Regeneron aims for FDA approval of extended dosing for EYLEA HD in AMD and DME, with a decision by April 2025. Pre-filled ...

Lined up for the FDA in the coming weeks are a cell-based gene therapy for a rare skin disease and two product expansions for ...

The stock's fall snapped a two-day winning streak.

Shares of Regeneron Pharmaceuticals Inc. REGN rose 1.43% to $554.18 Friday, on what proved to be an all-around great trading ...

High school senior Matteo Paz stunned the astronomy world by uncovering 1.5 million previously unknown cosmic objects using a ...

In a report released on April 11, Salveen Richter from Goldman Sachs maintained a Buy rating on Regeneron (REGN – Research Report), with a ...

Regeneron’s Eylea franchise remains resilient despite biosimilar competition. Read what makes REGN stock a Strong Buy despite ...

Yesafili, a vascular endothelial growth factor inhibitor, is used to treat several different types of ophthalmology ...